

PHIBRO ANIMAL HEALTH CORP
Form 10-Q
February 06, 2017
TABLE OF CONTENTS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number: 001-36410

Phibro Animal Health Corporation
(Exact name of registrant as specified in its charter)

Delaware 13-1840497
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21 07666-6712
Teaneck, New Jersey (Zip Code)
(Address of Principal Executive Offices)

(201) 329-7300
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Edgar Filing: PHIBRO ANIMAL HEALTH CORP - Form 10-Q

Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of January 30, 2017, there were 18,529,489 shares of the registrant's Class A common stock, par value \$0.0001 per share, and 20,887,811 shares of the registrant's Class B common stock, par value \$0.0001 per share, outstanding.

TABLE OF CONTENTS

PHIBRO ANIMAL HEALTH CORPORATION

TABLE OF CONTENTS

| | Page |
|--|------------------|
| PART I—FINANCIAL INFORMATION | |
| Item 1. | |
| Financial Statements (unaudited) | |
| <u>Consolidated Statements of Operations</u> | <u>3</u> |
| <u>Consolidated Statements of Comprehensive Income (Loss)</u> | <u>4</u> |
| <u>Consolidated Balance Sheets</u> | <u>5</u> |
| <u>Consolidated Statements of Cash Flows</u> | <u>6</u> |
| <u>Notes to Consolidated Financial Statements</u> | <u>7</u> |
| Item 2. | |
| <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>19</u> |
| Item 3. | |
| <u>Quantitative and Qualitative Disclosures About Market Risk</u> | <u>30</u> |
| Item 4. | |
| <u>Controls and Procedures</u> | <u>31</u> |
| PART II—OTHER INFORMATION | |
| Item 1. | |
| <u>Legal Proceedings</u> | <u>32</u> |
| Item 1A. | |
| <u>Risk Factors</u> | <u>32</u> |
| Item 2. | |
| <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>32</u> |
| Item 3. | |
| <u>Defaults Upon Senior Securities</u> | <u>32</u> |
| Item 4. | |
| <u>Mine Safety Disclosures</u> | <u>32</u> |
| Item 5. | |
| <u>Other Information</u> | <u>32</u> |
| Item 6. | |
| <u>Exhibits</u> | <u>32</u> |
| <u>SIGNATURES</u> | <u>34</u> |

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

| For the Periods Ended December 31 | Three Months | | Six Months | |
|--|--|------------|------------|------------|
| | 2016 | 2015 | 2016 | 2015 |
| | (unaudited) | | | |
| | (in thousands, except per share amounts) | | | |
| Net sales | \$ 191,598 | \$ 191,773 | \$ 379,585 | \$ 378,893 |
| Cost of goods sold | 128,100 | 130,311 | 255,088 | 258,224 |
| Gross profit | 63,498 | 61,462 | 124,497 | 120,669 |
| Selling, general and administrative expenses | 40,870 | 38,841 | 80,056 | 76,190 |
| Operating income | 22,628 | 22,621 | 44,441 | 44,479 |
| Interest expense, net | 3,872 | 3,967 | 7,779 | 7,786 |
| Foreign currency (gains) losses, net | (548) | 2,557 | (214) | (2,896) |
| Income before income taxes | 19,304 | 16,097 | 36,876 | 39,589 |
| Provision (benefit) for income taxes | 5,887 | (14,081) | 11,282 | (9,342) |
| Net income | \$ 13,417 | \$ 30,178 | \$ 25,594 | \$ 48,931 |
| Net income per share | | | | |
| basic | \$ 0.34 | \$ 0.77 | \$ 0.65 | \$ 1.25 |
| diluted | \$ 0.34 | \$ 0.75 | \$ 0.64 | \$ 1.22 |
| Weighted average common shares outstanding | | | | |
| basic | 39,411 | 39,163 | 39,409 | 39,128 |
| diluted | 40,002 | 39,978 | 39,954 | 39,995 |
| Dividends per share | \$ 0.10 | \$ 0.10 | \$ 0.20 | \$ 0.20 |

The accompanying notes are an integral part of these consolidated financial statements

3

TABLE OF CONTENTSPHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

| For the Periods Ended December 31 | Three Months | | Six Months | |
|--|----------------|-----------|------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| | (unaudited) | | | |
| | (in thousands) | | | |
| Net income | \$ 13,417 | \$ 30,178 | \$ 25,594 | \$ 48,931 |
| Change in fair value of derivative instruments | 270 | 1,909 | 304 | (2,994) |
| Foreign currency translation adjustment | (2,296) | 2,014 | (3,189) | (19,715) |
| Unrecognized net pension gains (losses) | 4,671 | 508 | 11,840 | 892 |
| (Provision) benefit for income taxes | (1,894) | (1,371) | (4,644) | 2,315 |
| Other comprehensive income (loss) | 751 | 3,060 | 4,311 | (19,502) |
| Comprehensive income (loss) | \$ 14,168 | \$ 33,238 | \$ 29,905 | \$ 29,429 |

The accompanying notes are an integral part of these consolidated financial statements

4

TABLE OF CONTENTSPHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

| As of | December 31, 2016 | June 30, 2016 |
|--|---|------------------|
| | (unaudited) | |
| | (in thousands, except share and per share amounts) | |
| ASSETS | | |
| Cash and cash equivalents | \$ 39,220 | \$ 33,605 |
| Accounts receivable, net | 124,131 | 123,790 |
| Inventories, net | 158,819 | 167,691 |
| Other current assets | 16,839 | 17,745 |
| Total current assets | 339,009 | 342,831 |
| Property, plant and equipment, net | 127,180 | 127,323 |
| Intangibles, net | 57,134 | 60,095 |
| Goodwill | 21,121 | 21,121 |
| Other assets | 47,841 | 56,465 |
| Total assets | \$ 592,285 | \$ 607,835 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current portion of long-term debt | \$ 2,901 | \$ 2,907 |
| Accounts payable | 54,826 | 60,167 |
| Accrued expenses and other current liabilities | 45,602 | 45,703 |
| Total current liabilities | 103,329 | 108,777 |
| Revolving credit facility | 48,500 | 69,000 |
| Long-term debt | 277,132 | 278,265 |
| Other liabilities | 50,711 | 61,313 |
| Total liabilities | 479,672 | 517,355 |
| Commitments and contingencies (Note 8) | | |
| Common stock, par value \$0.0001 per share; 300,000,000 Class A shares authorized, 18,529,095 and 18,519,757 shares issued and outstanding at December 31, 2016, and June 30, 2016, respectively; 30,000,000 Class B shares authorized, 20,887,811 shares issued and outstanding at December 31, 2016, and June 30, 2016 | 4 | 4 |
| Preferred stock, par value \$0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding | — | — |
| Paid-in capital | 118,409 | 118,299 |
| Retained earnings | 51,674 | 33,962 |
| Accumulated other comprehensive income (loss) | (57,474) | (61,785) |
| Total stockholders' equity | 112,613 | 90,480 |
| Total liabilities and stockholders' equity | \$ 592,285 | \$ 607,835 |

The accompanying notes are an integral part of these consolidated financial statements

TABLE OF CONTENTSPHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

| For the Periods Ended December 31 | Six Months | |
|--|----------------|-----------|
| | 2016 | 2015 |
| | (unaudited) | |
| | (in thousands) | |
| OPERATING ACTIVITIES | | |
| Net income | \$ 25,594 | \$ 48,931 |
| Adjustments to reconcile net income to net cash provided (used) by operating activities: | | |
| Depreciation and amortization | 12,762 | 10,822 |
| Amortization of debt issuance costs and debt discount | 508 | 484 |
| Acquisition-related accrued compensation | 840 | 840 |
| Acquisition-related accrued interest | 855 | 689 |
| Pension settlement cost | 1,702 | — |
| Deferred income taxes | 3,736 | (21,615) |
| Foreign currency (gains) losses, net | 293 | (2,790) |
| Other | 310 | 149 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable, net | (1,583) | (6,885) |
| Inventories, net | 7,017 | (12,794) |
| Other current assets | 919 | (309) |
| Other assets | (512) | (3,343) |
| Accounts payable | (4,667) | (4,842) |
| Accrued expenses and other liabilities | (41) | (3,733) |
| Net cash provided (used) by operating activities | 47,733 | 5,604 |
| INVESTING ACTIVITIES | | |
| Capital expenditures | (10,564) | (17,653) |
| Other, net | (201) | 263 |
| Net cash provided (used) by investing activities | (10,765) | (17,390) |
| FINANCING ACTIVITIES | | |
| Revolving credit facility borrowings | 73,000 | 100,500 |
| Revolving credit facility repayments | (93,500) | (83,500) |
| Payments of long-term debt, capital leases and other | (2,776) | (2,466) |
| Proceeds from common shares issued | 110 | 2,078 |
| Dividends paid | (7,882) | (7,827) |
| Net cash provided (used) by financing activities | (31,048) | 8,785 |
| Effect of exchange rate changes on cash | (305) | (843) |
| Net increase (decrease) in cash and cash equivalents | 5,615 | (3,844) |
| Cash and cash equivalents at beginning of period | 33,605 | 29,216 |
| Cash and cash equivalents at end of period | \$ 39,220 | \$ 25,372 |

The accompanying notes are an integral part of these consolidated financial statements

6

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share amounts)

(unaudited)

1.

Description of Business

Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (collectively, the “Company”) is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, cattle, dairy and aquaculture. The Company is also a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this report to “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries.

The unaudited consolidated financial information for the three and six months ended December 31, 2016 and 2015, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the “Annual Report”), filed with the Securities and Exchange Commission on August 29, 2016 (File no. 001-36410). In the opinion of management, these financial statements include all adjustments necessary for a fair statement of financial position, results of operations and cash flows for the interim periods, and the adjustments are of a normal and recurring nature. The financial results for any interim period are not necessarily indicative of the results for the full year. The consolidated balance sheet information as of June 30, 2016, was derived from the audited consolidated financial statements, which include the accounts of Phibro and its consolidated subsidiaries, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The unaudited consolidated financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report.

The consolidated financial statements include the accounts of Phibro and its consolidated subsidiaries. The decision whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective control over the entity. Intercompany balances and transactions have been eliminated in the consolidated financial statements.

2.

Summary of Significant Accounting Policies and New Accounting Standards

Our significant accounting policies are described in the notes to the consolidated financial statements included in our Annual Report. As of December 31, 2016, there have been no material changes to any of the significant accounting policies contained therein, except for the application of Accounting Standards Update (“ASU”) 2015-03, Interest—Imputation of Interest (Subtopic 835-30), as of July 1, 2016. Prior periods have been adjusted to reflect the retrospective application of this guidance. For further discussion, see “—New Accounting Standards.”

Revisions of Previously Issued Financial Statements

During the three months ended June 30, 2016, the Company determined that amortization expense related to product-related intangible assets should be recorded in cost of goods sold rather than in selling, general and administrative expense within the consolidated statement of operations. The Company has revised its prior period financial statements, to correct the classification of amortization expense to increase cost of goods sold and reduce gross profit and selling, general and administrative expenses by \$954 and \$1,907 for the three and six months ended December 31, 2015, respectively. These revisions had no impact on the Company’s previously reported net income (loss) or cash flows. The Company evaluated the impact of the revisions on prior periods, assessing materiality quantitatively and qualitatively, and concluded the errors were not material to any previously issued financial statements.

Net Income per Share and Weighted Average Shares

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period.

7

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Diluted net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the reporting period after giving effect to potential dilutive common shares equivalents resulting from the assumed exercise of stock options. For the three and six months ended December 31, 2016 and 2015, all common share equivalents were included in the calculation of diluted net income per share.

| For the Periods Ended December 31 | Three Months | | Six Months | |
|---|--------------|-----------|------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Net income | \$ 13,417 | \$ 30,178 | \$ 25,594 | \$ 48,931 |
| Weighted average number of shares – basic | 39,411 | 39,163 | 39,409 | 39,128 |
| Dilutive effect of stock options | 591 | 815 | 545 | 867 |
| Weighted average number of shares – diluted | 40,002 | 39,978 | 39,954 | 39,995 |
| Net income per share | | | | |
| basic | \$ 0.34 | \$ 0.77 | \$ 0.65 | \$ 1.25 |
| diluted | \$ 0.34 | \$ 0.75 | \$ 0.64 | \$ 1.22 |

Dividends

We declared and paid quarterly cash dividends of \$0.10 per share, totaling \$3,941 and \$7,882, during the three and six months ended December 31, 2016, respectively, to holders of our Class A common stock and Class B common stock.

New Accounting Standards

Financial Accounting Standards Board (“FASB”) ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, supersedes the current guidance by establishing a one-step goodwill impairment test. This new guidance requires an entity to compare the fair value of a reporting unit to its carrying amount, and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. This ASU is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early application is permitted for goodwill impairment tests performed after January 1, 2017. We will apply this guidance when performing our next goodwill impairment test. We do not expect adoption of this guidance to have a material effect on our consolidated financial statements.

ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, provides specific guidance for the classification of certain transactions within the statement of cash flows. The issues addressed by this guidance include, but are not limited to, debt prepayments or debt extinguishment costs, contingent consideration payments made after a business combination and proceeds from the settlement of insurance claims. This ASU is effective for annual reporting periods beginning after December 15, 2017. Early application is permitted, as long as all provisions under the guidance are applied simultaneously. The provisions of this guidance are to be applied using a retrospective transition approach. We do not expect adoption of this guidance to have a material effect on our consolidated financial statements.

ASU 2016-02, Leases (Topic 842), supersedes the current lease accounting guidance and requires an entity to recognize assets and liabilities for both financing and operating leases on the balance sheet and requires additional qualitative and quantitative disclosures regarding leasing arrangements. This ASU is effective for annual reporting periods beginning after December 15, 2018. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.

ASU 2015-11, Inventory (Topic 330), requires entities to measure inventory at the lower of cost and net realizable value (“NRV”). NRV is defined as “the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The guidance is

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

effective for annual periods beginning after December 15, 2016, and interim periods within those years. We do not expect adoption of this guidance to have a material effect on our consolidated financial statements.

ASU 2015-05, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) provides guidance regarding the treatment of cloud computing arrangements and if an arrangement includes a software license. We adopted this guidance during the three months ended September 30, 2016, and it had no material impact on our consolidated financial statements.

ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30), requires debt issuance costs to be presented as a reduction of the related liability. These costs were previously included in other assets. Debt issuance costs associated with line-of-credit arrangements may continue to be recognized in other assets. We adopted this guidance during the three months ended September 30, 2016, and applied the guidance retrospectively. Debt issuance costs of \$2,538 as of June 30, 2016, have been presented as a reduction in long-term debt on our consolidated balance sheets.

ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), requires management to assess an entity's ability to continue as a going concern within one year after the issuance date of the financial statements, and to provide related footnote disclosures in certain circumstances. Management will need to consider relevant conditions that are known and reasonably knowable at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Under the new standard, the definition of substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in GAAP for loss contingencies. ASU 2014-15 will be effective for annual periods ending after December 15, 2016, and for annual periods and interim periods thereafter. We do not expect adoption of this guidance to have a material effect on our consolidated financial statements.

ASU 2014-09, Revenue from Contracts with Customers (Topic 606), establishes principles for the recognition of revenue from contracts with customers. The underlying principle is to identify the performance obligations of a contract, allocate the revenue to each performance obligation and then to recognize revenue when the company satisfies a specific performance obligation of the contract. ASU 2015-14, Deferral of the Effective Date, amended ASU 2014-09, resulting in a one-year deferral of the effective date. ASU 2016-08, Principal versus Agent Considerations; ASU 2016-10, Identifying Performance Obligations and Licensing; and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients also amended ASU 2014-09. The amendments are effective concurrent with the effective date for ASU 2014-09 for annual periods beginning after December 15, 2017, and interim periods within those years. We are evaluating the impact of adoption of this guidance on our consolidated financial statements.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

3.
Statements of Operations—Additional Information

| For the Periods Ended December 31 | Three Months | | Six Months | |
|---|--------------|----------|------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Interest expense, net | | | | |
| Term B loan | \$ 2,866 | \$ 2,927 | \$ 5,771 | \$ 5,862 |
| Revolving credit facility | 731 | 342 | 1,686 | 602 |
| Amortization of debt issuance costs and debt discount | 255 | 242 | 508 | 484 |
| Acquisition-related accrued interest | 462 | 344 | 855 | 689 |
| Other | 47 | 169 | 128 | 255 |
| Interest expense | 4,361 | 4,024 | 8,948 | 7,892 |
| Interest (income) | (489) | (57) | (1,169) | (106) |
| | \$ 3,872 | \$ 3,967 | \$ 7,779 | \$ 7,786 |
| Depreciation and amortization | | | | |
| Depreciation of property, plant and equipment | \$ 4,952 | \$ 4,075 | \$ 9,683 | \$ 8,186 |
| Amortization of intangible assets | 1,434 | 1,260 | 2,962 | 2,519 |
| Amortization of other assets | 58 | 58 | 117 | 117 |
| | \$ 6,444 | \$ 5,393 | \$ 12,762 | \$ 10,822 |

The provision (benefit) for income taxes for the three and six months ended December 31, 2015, included a benefit of \$18,787 due to the reversal of the valuation allowance we previously had recorded against domestic deferred tax assets. Based on continued domestic profitability, we concluded that it was more likely than not that the value of domestic deferred tax assets would be realized, and it was no longer necessary to maintain a valuation allowance.

4.
Balance Sheets—Additional Information

| As of | December 31, 2016 | June 30, 2016 |
|-----------------|----------------------|------------------|
| Inventories | | |
| Raw materials | \$ 56,299 | \$ 51,369 |
| Work-in-process | 9,455 | 8,074 |
| Finished goods | 93,065 | 108,248 |
| | \$ 158,819 | \$ 167,691 |

Goodwill balances did not change during the six months ended December 31, 2016.

We evaluate our investments in equity method investees for impairment if circumstances indicate that the fair value of the investment may be impaired. The assets underlying a \$4,094 equity investment are currently idled; we have concluded the investment is not currently impaired, based on expected future operating cash flows and/or disposal value.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

| As of | December 31, 2016 | June 30, 2016 |
|--|----------------------|------------------|
| Accrued expenses and other current liabilities | | |
| Employee related | \$ 21,011 | \$ 21,712 |
| Commissions and rebates | 4,572 | 3,722 |
| Insurance related | 1,617 | 1,780 |
| Professional fees | 3,930 | 3,573 |
| Income and other taxes | 3,007 | 1,910 |
| Deferred consideration on acquisitions | — | 1,250 |
| Other | 11,465 | 11,756 |
| | \$ 45,602 | \$ 45,703 |

| As of | December 31, 2016 | June 30, 2016 |
|---|----------------------|------------------|
| Accumulated other comprehensive income (loss) | | |
| Derivative instruments | \$ 2,959 | \$ 2,655 |
| Foreign currency translation adjustment | (45,093) | (41,904) |
| Unrecognized net pension gains (losses) | (19,137) | (30,977) |
| (Provision) benefit for income taxes on derivative instruments | (1,664) | (1,548) |
| (Provision) benefit for incomes taxes on long-term intercompany investments | 8,166 | 8,166 |
| (Provision) benefit for income taxes on pension gains (losses) | (2,705) | 1,823 |
| | \$ (57,474) | \$ (61,785) |

5.

Debt

Revolving Credit Facility and Term B Loan

We have a revolving credit facility (the “Revolver”), where we can borrow up to \$200,000, subject to the terms of the agreement, and a term B loan (the “Term B Loan,” and together with the Revolver, the “Credit Facilities”). The Revolver, as amended, has applicable margins equal to 2.50%, 2.75% or 3.00%, in the case of LIBOR loans and 1.50%, 1.75% or 2.00%, in the case of base rate loans; the applicable margins are based on the First Lien Net Leverage Ratio. The Term B Loan has applicable margins equal to 3.00% with regards to LIBOR loans and 2.00% regarding base rate loans. The LIBOR rate on the Term B Loan is subject to a floor of 1.00%.

The Revolver requires, among other things, the maintenance of a maximum consolidated first lien net debt to consolidated EBITDA leverage ratio, calculated on a trailing four quarter basis, and contains an acceleration clause should an event of default (as defined in the agreement governing the Credit Facilities) occur. As of December 31, 2016, we were in compliance with the covenants of the Credit Facilities.

As of December 31, 2016, we had \$48,500 in borrowings under the Revolver and had outstanding letters of credit of \$14,518 leaving \$136,982 available for borrowings and letters of credit under the Revolver. We obtain letters of credit in connection with certain regulatory and insurance obligations and other contractual obligations. The tenors of these letters of credit are all one year or less.

The weighted-average interest rates for the Revolver and Term B Loan were 3.30% and 4.00%, respectively, for the six months ended December 31, 2016.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Long-Term Debt

| As of | December 31, 2016 | June 30, 2016 |
|---|----------------------|------------------|
| Term B Loan due April 2021 | \$ 282,750 | \$ 284,200 |
| Capitalized lease obligations | 1 | 7 |
| | 282,751 | 284,207 |
| Unamortized debt issuance costs and debt discount | (2,718) | (3,035) |
| Less: current maturities | (2,901) | (2,907) |
| | \$ 277,132 | \$ 278,265 |

6.

Related Party Transactions

Certain relatives of Jack C. Bendheim provided services to us as employees or consultants and received aggregate compensation and benefits of \$445 and \$1,047 during the three and six months ended December 31, 2016, respectively, and \$428 and \$1,127 during the three and six months ended December 31, 2015, respectively. Mr. Bendheim has sole authority to vote shares of our stock owned by BFI Co., LLC, an investment vehicle of the Bendheim family.

7.

Employee Benefit Plans

The Company maintains a noncontributory defined benefit pension plan for all domestic nonunion employees employed on or prior to December 31, 2013, who meet certain requirements of age, length of service and hours worked per year. Plan benefits are based upon years of service and average compensation, as defined. In July 2016, we amended our domestic noncontributory defined benefit pension plan to eliminate credit for future service and compensation increases, effective as of September 30, 2016. The amendment resulted in a curtailment of the pension plan. During the three months ended September 30, 2016, we recorded a pension curtailment gain of \$6,822 in other comprehensive income and an offsetting reduction in the liability for pension benefits included in other liabilities. We also modified the 401(k) retirement savings plan, effective October 1, 2016, to include, for all domestic employees, a non-elective Company contribution of 3% of compensation and an additional discretionary contribution of up to 4% of compensation, depending on the employee's age and years of service. Separately, we offered a lump sum settlement option to certain pension plan participants. During the three months ended December 31, 2016, we recognized a partial settlement of the pension plan with respect to the lump sum settlement, which resulted in a charge to the consolidated statement of operations of \$1,702, which we recorded as a component of selling, general and administrative expenses.

Net periodic pension expense was:

| For the Periods Ended December 31 | Three Months | | Six Months | |
|---|--------------|----------|------------|----------|
| | 2016 | 2015 | 2016 | 2015 |
| Service cost – benefits earned during the period | \$ 284 | \$ 751 | \$ 845 | \$ 1,470 |
| Interest cost on benefit obligation | 505 | 757 | 1,048 | 1,446 |
| Expected return on plan assets | (843) | (846) | (1,706) | (1,588) |
| Amortization of net actuarial (gain) loss and prior service costs | 105 | 508 | 452 | 892 |
| Settlement cost | 1,702 | — | 1,702 | — |
| Net periodic pension expense | \$ 1,753 | \$ 1,170 | \$ 2,341 | \$ 2,220 |

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

8.
Commitments and Contingencies

Environmental

Our operations and properties are subject to extensive federal, state, local and foreign laws and regulations, including those governing pollution; protection of the environment; the use, management, and release of hazardous materials, substances and wastes; air emissions; greenhouse gas emissions; water use, supply and discharges; the investigation and remediation of contamination; the manufacture, distribution, and sale of regulated materials, including pesticides; the importing, exporting and transportation of products; and the health and safety of our employees (collectively, “Environmental Laws”). As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties, and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict.

While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with, Environmental Laws; however, we cannot predict with certainty the effect of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance.

The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

The United States Environmental Protection Agency (the “EPA”) is investigating and planning for the remediation of offsite contaminated groundwater that has migrated from the Omega Chemical Corporation Superfund Site (“Omega Chemical Site”), which is upgradient of a facility in Santa Fe Springs, California, operated by our subsidiary Phibro-Tech, Inc. (“Phibro-Tech”). The EPA has named Phibro-Tech and certain other subsidiaries of PAHC as potentially responsible parties (“PRPs”) due to groundwater contamination from Phibro-Tech’s Santa Fe Springs facility that has allegedly commingled with contaminated groundwater from the Omega Chemical Site. In September 2012, the EPA notified approximately 140 PRPs, including Phibro-Tech and the other subsidiaries, that they have been identified as potentially responsible for remedial action for the groundwater plume affected by the Omega Chemical Site and for EPA oversight and response costs. Phibro-Tech contends that groundwater contamination at its site is due to historical operations that pre-date Phibro-Tech and/or contaminated groundwater that has migrated from upgradient properties. In addition, a successor to a prior owner of the Phibro-Tech site has asserted that PAHC and Phibro-Tech are obligated to provide indemnification for its potential liability and defense costs relating to the groundwater plume affected by the Omega Chemical Site. Phibro-Tech has vigorously contested this position and has asserted that the successor to the prior owner is required to indemnify Phibro-Tech for its potential liability and defense costs. Furthermore, a nearby property owner has filed a complaint in the Superior Court of the State of California against many of the PRPs allegedly

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for alleged contamination of groundwater underneath its property, and a group of companies that sent chemicals to the Omega Chemical Site for processing and recycling has filed a complaint under CERCLA, RCRA and the common law public nuisance doctrine in the United States District Court for the Central District of California against many of the PRPs allegedly associated with the groundwater plume affected by the Omega Chemical Site (including Phibro-Tech) for contribution toward past and future costs associated with the investigation and remediation of the groundwater plume affected by the Omega Chemical Site. Due to the ongoing nature of the EPA's investigation and Phibro-Tech's dispute with the prior owner's successor, at this time we cannot predict with any degree of certainty what, if any, liability Phibro-Tech or the other subsidiaries may ultimately have for investigation, remediation and the EPA oversight and response costs associated with the affected groundwater plume.

Based upon information available, to the extent such costs can be estimated with reasonable certainty, we estimated the cost for further investigation and remediation of identified soil and groundwater problems at operating sites, closed sites and third-party sites, and closure costs for closed sites, to be \$7,211 and \$7,024 at December 31, 2016, and June 30, 2016, respectively, which is included in current and long-term liabilities on the consolidated balance sheets. However, future events, such as new information, changes in existing Environmental Laws or their interpretation, and more vigorous enforcement policies of regulatory agencies, may give rise to additional expenditures or liabilities that could be material. For all purposes of the discussion under this caption and elsewhere in this report, it should be noted that we take and have taken the position that neither PAHC nor any of our subsidiaries is liable for environmental or other claims made against one or more of our other subsidiaries or for which any of such other subsidiaries may ultimately be responsible.

Claims and Litigation

PAHC and its subsidiaries are party to a number of claims and lawsuits arising out of the normal course of business including product liability, payment disputes and governmental regulation. Certain of these actions seek damages in various amounts. In many cases, such claims are covered by insurance. We believe that none of the claims or pending lawsuits, either individually or in the aggregate, will have a material adverse effect on our financial position, results of operations, cash flows or liquidity.

9.

Derivatives

We monitor our exposure to foreign currency exchange rates and use derivatives (currency option contracts) to manage certain of these risks. These derivatives generally have an expiration/maturity of two years or less and are intended to hedge cash flows related to the purchase of inventory. We designate derivatives as a hedge of a forecasted transaction or of the variability of the cash flows to be received or paid in the future related to a recognized asset or liability (cash flow hedge). We record the portion of the changes in the value of the derivative, related to a hedged asset or liability (the effective portion), in accumulated other comprehensive income (loss). As the hedged item is sold, we recognize the gain or loss recorded in accumulated other comprehensive income (loss) to the consolidated statements of operations on the same line where the hedged item is charged when released/sold. We immediately recognize in the consolidated statements of operations in the same line as the hedged item, the portion of the changes in fair value of derivatives used as cash flow hedges that is not offset by changes in the expected cash flows related to a recognized asset or liability (the ineffective portion).

We routinely assess whether the derivatives used to hedge transactions are effective. If we determine that a derivative ceases to be an effective hedge, we discontinue hedge accounting in the period of the assessment for that derivative, and immediately recognize any unrealized gains or losses related to the fair value of that derivative in the consolidated statements of operations.

We record derivatives at fair value in the consolidated balance sheets. For additional details regarding fair value, see "—Fair Value Measurements."

14

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following table details the Company's outstanding derivatives that are designated and effective as cash flow hedges as of December 31, 2016:

| Instrument | Hedge | Notional Amount at December 31, 2016 | Fair value as of | |
|------------|----------------------|---|----------------------|------------------|
| | | | December 31, 2016 | June 30, 2016 |
| Options | Brazilian Real calls | R\$78,000 | \$ 2,982 | \$ 3,027 |
| Options | Brazilian Real puts | R\$78,000 | \$ (23) | \$ (372) |

The fair values at December 31, 2016, are unrealized and will fluctuate based on future exchange rates until the derivative contracts mature. Other comprehensive income (loss) for the three and six months ended December 31, 2016, included \$270 and \$304, respectively, of net unrecognized gains related to these contracts. Accumulated other comprehensive income (loss) at December 31, 2016, included \$2,959 of net unrecognized gains on derivative instruments; we estimate that \$362 of those gains will be recognized in earnings within the next twelve months. At June 30, 2016, realized losses of \$1,528 related to matured contracts were recorded as a component of inventory. We recognized \$393 and \$1,528 of these losses in cost of goods sold during the three and six months ended December 31, 2016, respectively. We recognize gains (losses) related to these derivative instruments as a component of cost of goods sold at the time the hedged item is sold.

10.

Fair Value Measurements

Fair value is defined as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Financial assets and liabilities are measured at fair value using the three-level valuation hierarchy for disclosure of fair value measurements. The determination of the applicable level within the hierarchy of a particular asset or liability depends on the inputs used in the valuation as of the measurement date, notably the extent to which the inputs are market-based (observable) or internally derived (unobservable). Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs based on a company's own assumptions about market participant assumptions developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—

Significant observable inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly through corroboration with observable market data.

Level 3—

Unobservable inputs for which there is little or no market data available, and that are significant to the overall fair value measurement, are employed that require the reporting entity to develop its own assumptions.

In assessing the fair value of financial instruments at September 30, 2016, and June 30, 2016, we used a variety of methods and assumptions that were based on estimates of market conditions and risks existing at the time.

Current Assets and Liabilities

We consider the carrying amounts of current assets and current liabilities to be representative of their fair value because of the current nature of these items.

Letters of Credit

We obtain letters of credit in connection with certain regulatory and insurance obligations, inventory purchases and other contractual obligations. The carrying values of these letters of credit are considered to be representative of their

fair values because of the nature of the instruments. The tenors of these letters of credit are all one year or less.
15

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Long Term Debt

We record the Term B Loan and the Revolver at book value in our consolidated financial statements. We believe the carrying value of the Term B Loan is approximately equal to the fair value, which is based on quoted broker prices that are Level 2 inputs. We believe the carrying value of the Revolver is approximately equal to the fair value due to the variable nature of the instrument.

Deferred Consideration on Acquisitions

We estimated the fair value of the deferred contingent consideration on acquisitions using the income approach, based on the Company's current sales forecast related to the acquired business.

Derivatives

We determine the fair value of derivative instruments based upon pricing models using observable market inputs for these types of financial instruments, such as spot and forward currency translation rates.

| As of | December 31, 2016 | | | June 30, 2016 | | |
|---|-------------------|----------|------------|---------------|----------|------------|
| | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 |
| Derivatives asset | \$ — | \$ 2,959 | \$ — | \$ — | \$ 2,655 | \$ — |
| Deferred contingent consideration on acquisitions | \$ — | \$ — | \$ (7,530) | \$ — | \$ — | \$ (6,745) |

The table below provides a summary of the changes in the fair value of Level 3 liabilities:

| | |
|--------------------------------------|------------|
| Balance, June 30, 2016 | \$ (6,745) |
| Acquisition-related accrued interest | (855) |
| Payment | 70 |
| Balance, December 31, 2016 | \$ (7,530) |

11.

Business Segments

The Animal Health segment manufactures and markets a broad range of products for food animals, including poultry, swine, cattle, dairy and aquaculture. The business includes net sales of medicated feed additives and other related products, nutritional specialty products and vaccines. The Mineral Nutrition segment manufactures and markets a broad range of trace mineral products for food animals. The Performance Products segment manufactures and markets a variety of products for use in the personal care, automotive, industrial chemical and chemical catalyst industries. We evaluate performance and allocate resources based on the Animal Health, Mineral Nutrition and Performance Products segments. Certain of our costs and assets are not directly attributable to these segments and such costs are referred to as Corporate. We do not allocate such items to the principal segments because they are not used to evaluate their operating results or financial position.

We evaluate performance of our segments based on Adjusted EBITDA. We define Adjusted EBITDA as income before income taxes plus (a) interest expense, net, (b) depreciation and amortization, (c) (income) loss from, and disposal of, discontinued operations, (d) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (e) certain items that we consider to be unusual, non-operational or non-recurring.

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The accounting policies of our segments are the same as those described in the summary of significant accounting policies included herein.

| For the Periods Ended December 31 | Three Months | | Six Months | |
|---|--------------|------------|------------|------------|
| | 2016 | 2015 | 2016 | 2015 |
| Net sales | | | | |
| MFAs and other | \$ 77,475 | \$ 85,569 | \$ 160,894 | \$ 171,090 |
| Nutritional Specialties | 29,247 | 24,222 | 55,551 | 46,592 |
| Vaccines | 16,951 | 11,713 | 31,729 | 23,956 |
| Animal Health | 123,673 | 121,504 | 248,174 | 241,638 |
| Mineral Nutrition | 56,699 | 58,853 | 108,291 | 113,322 |
| Performance Products | 11,226 | 11,416 | 23,120 | 23,933 |
| Total segments | \$ 191,598 | \$ 191,773 | \$ 379,585 | \$ 378,893 |
| Depreciation and amortization | | | | |
| Animal Health | \$ 5,011 | \$ 3,829 | \$ 9,909 | \$ 7,705 |
| Mineral Nutrition | 542 | 612 | 1,084 | 1,220 |
| Performance Products | 235 | 194 | 453 | 388 |
| Total segments | \$ 5,788 | \$ 4,635 | \$ 11,446 | \$ 9,313 |
| Adjusted EBITDA | | | | |
| Animal Health | \$ 34,609 | \$ 32,351 | \$ 67,228 | \$ 63,827 |
| Mineral Nutrition | 4,741 | 4,189 | 8,729 | 7,349 |
| Performance Products | 260 | (8) | 1,002 | 78 |
| Total segments | \$ 39,610 | \$ 36,532 | \$ 76,959 | \$ 71,254 |
| Reconciliation of income before income taxes to Adjusted EBITDA | | | | |
| Income before income taxes | \$ 19,304 | \$ 16,097 | \$ 36,876 | \$ 39,589 |
| Interest expense, net | 3,872 | 3,967 | 7,779 | 7,786 |
| Depreciation and amortization – Total segments | 5,788 | 4,635 | 11,446 | 9,313 |
| Depreciation and amortization – Corporate | 656 | 758 | 1,316 | 1,509 |
| Corporate costs | 8,416 | 8,098 | 15,940 | 15,113 |
| Acquisition-related accrued compensation | 420 | 420 | 840 | 840 |
| Acquisition-related transaction costs | — | — | 1,274 | — |
| Pension settlement cost | 1,702 | — | 1,702 | — |
| Foreign currency (gains) losses, net | (548) | 2,557 | (214) | (2,896) |
| Adjusted EBITDA – Total segments | \$ 39,610 | \$ 36,532 | \$ 76,959 | \$ 71,254 |
| As of | December 31, | June 30, | | |
| | 2016 | 2016 | | |
| Identifiable assets | | | | |
| Animal Health | \$ 436,174 | \$ 444,751 | | |

Edgar Filing: PHIBRO ANIMAL HEALTH CORP - Form 10-Q

| | | |
|----------------------|------------|------------|
| Mineral Nutrition | 56,615 | 57,939 |
| Performance Products | 21,246 | 21,557 |
| Total segments | 514,035 | 524,247 |
| Corporate | 78,250 | 83,588 |
| Total | \$ 592,285 | \$ 607,835 |

17

TABLE OF CONTENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Animal Health segment includes all goodwill of the Company. The Animal Health segment includes advances to and investment in an equity method investee of \$4,094 and \$4,076 as of December 31, 2016, and June 30, 2016, respectively. The Performance Products segment includes an investment in an equity method investee of \$452 and \$504 as of December 31, 2016, and June 30, 2016, respectively. Corporate assets include cash and cash equivalents, debt issuance costs related to the Revolver, income tax related assets and certain other assets.

18

TABLE OF CONTENTS

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is provided to assist readers in understanding our performance and summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented below. This MD&A should be read in conjunction with our consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance or our future expectations as a result of various factors, such as those discussed in "Forward-Looking Statements" and "Risk Factors."

Overview of our business

Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for food animals including poultry, swine, cattle, dairy and aquaculture. We also are a manufacturer and marketer of performance products for use in the personal care, automotive, industrial chemical and chemical catalyst industries.

Trends and uncertainties

Our business depends heavily on a healthy and growing livestock industry. Some in the public perceive risks to human health related to the consumption of food derived from animals that utilize certain of our products, including certain of our medicated feed additives products. In particular, there is increased focus, primarily in the United States, on the use of medically important antibacterials, as defined by the FDA. Medically important antibacterials include classes that are prescribed in animal and human health and are listed in the Appendix of the FDA-CVM Guidance for Industry (GFI) #152. Our products that contain virginiamycin, oxytetracycline or neomycin have previously been classified by the FDA as medically important antibacterials. This may lead to a decline in the demand for and production of food products derived from animals that utilize our products and, in turn, demand for our products. Livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of nutrition and health-related concerns, animal rights, and other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including us. In addition, campaigns by interest groups, activists and others with respect to perceived risks associated with the use of our products in animals, including position statements by livestock producers and their customers based on non-use of certain medicated products in livestock production, whether or not scientifically-supported, could affect public perceptions and reduce the use of our products. Those adverse consumer views related to the use of one or more of our products in animals could have a material adverse effect on our financial condition and results of operations.

Our sales in the United States of products classified by the FDA as medically important antibacterials were approximately \$32 million for the twelve months ended December 31, 2016, a decrease of \$5 million compared with the twelve months ended June 30, 2016.

Our business is subject to product registration and authorization regulations. Changes in these regulations could have a material impact on our business. In April 2016, the FDA began initial steps to withdraw approval of Mecadox (carbadox), due to concerns that certain residues from the product may persist in tissues for longer than previously determined. This initial action by the FDA does not prohibit the sale or use of Mecadox in the United States. Mecadox has been approved and sold in the United States for more than 40 years and is a widely used treatment for controlling bacterial diseases including Salmonella and swine dysentery. Mecadox is not used in human medicine and the class of drug is not considered a medically important antibacterial. The approved Mecadox label requires a 42-day withdrawal period pre-harvesting, and to date we have not seen any hazardous residues of carbadox being detected from pig meat treated in accordance with the approved label. We have complete confidence in the safety of Mecadox. In response to FDA inquiries several years ago, we began rigorous new studies of the continued safety of the product when used in accordance with the label. Our studies were completed in July 2016, and we submitted our data, analyses and information to the FDA that we believe support the continued safe use of

TABLE OF CONTENTS

Mecadox. As of December 31, 2016, we await the response of the FDA as the timing of their response to our submission is not subject to a predetermined deadline. Should we be unable to successfully defend the safety of the product, the loss of Mecadox sales would have a negative impact to the results of our operations.

Our sales of Mecadox in the United States were approximately \$14 million for the twelve months ended December 31, 2016, a decrease of \$1 million compared with the twelve months ended June 30, 2016, as a result of normal variation in customer order patterns.

Analysis of the consolidated statements of operations

Summary Results of Operations

| For the Periods Ended December 31 | Three Months | | | | Six Months | | | |
|---|--|------------|-------------|-------|------------|------------|-------------|-------|
| | 2016 | 2015 | Change | | 2016 | 2015 | Change | |
| | (in thousands, except per share amounts and percentages) | | | | | | | |
| Net sales | \$ 191,598 | \$ 191,773 | \$ (175) | (0)% | \$ 379,585 | \$ 378,893 | \$ 692 | 0% |
| Gross profit | 63,498 | 61,462 | 2,036 | 3% | 124,497 | 120,669 | 3,828 | 3% |
| Selling, general and administrative expenses | 40,870 | 38,841 | 2,029 | 5% | 80,056 | 76,190 | 3,866 | 5% |
| Operating income | 22,628 | 22,621 | 7 | 0% | 44,441 | 44,479 | (38) | (0)% |
| Interest expense, net | 3,872 | 3,967 | (95) | (2)% | 7,779 | 7,786 | (7) | (0)% |
| Foreign currency (gains) losses, net | (548) | 2,557 | (3,105) | * | (214) | (2,896) | 2,682 | * |
| Income before income taxes | 19,304 | 16,097 | 3,207 | 20% | 36,876 | 39,589 | (2,713) | (7)% |
| Provision (benefit) for income taxes | 5,887 | (14,081) | 19,968 | * | 11,282 | (9,342) | 20,624 | * |
| Net income | \$ 13,417 | \$ 30,178 | \$ (16,761) | (56)% | \$ 25,594 | \$ 48,931 | \$ (23,337) | (48)% |
| Net income per share | | | | | | | | |
| basic | \$ 0.34 | \$ 0.77 | \$ (0.43) | | \$ 0.65 | \$ 1.25 | \$ (0.60) | |
| diluted | \$ 0.34 | \$ 0.75 | \$ (0.41) | | \$ 0.64 | \$ 1.22 | \$ (0.58) | |
| Weighted average number of shares outstanding | | | | | | | | |
| basic | 39,411 | 39,163 | | | 39,409 | 39,128 | | |
| diluted | 40,002 | 39,978 | | | 39,954 | 39,995 | | |

Edgar Filing: PHIBRO ANIMAL HEALTH CORP - Form 10-Q

| | | | | |
|--|-------|---------|-------|---------|
| Ratio to net sales | | | | |
| Gross profit | 33.1% | 32.0% | 32.8% | 31.8% |
| Selling, general and administrative expenses | 21.3% | 20.3% | 21.1% | 20.1% |
| Operating income | 11.8% | 11.8% | 11.7% | 11.7% |
| Income before income taxes | 10.1% | 8.4% | 9.7% | 10.4% |
| Net income | 7.0% | 15.7% | 6.7% | 12.9% |
| Effective tax rate | 30.5% | (87.5)% | 30.6% | (23.6)% |

Certain amounts and percentages may reflect rounding adjustments.

*

Calculation not meaningful

TABLE OF CONTENTS

Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA

We report net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “—General description of non-GAAP financial measures” for descriptions of EBITDA and Adjusted EBITDA.

Segment net sales and Adjusted EBITDA:

| For the Periods Ended December 31 | Three Months | | | | Six Months | | | |
|--|------------------------------------|------------|------------|------|------------|------------|-------------|-------|
| | 2016 | 2015 | Change | | 2016 | 2015 | Change | |
| | (in thousands, except percentages) | | | | | | | |
| Net sales | | | | | | | | |
| MFAs and other | \$ 77,475 | \$ 85,569 | \$ (8,094) | (9)% | \$ 160,894 | \$ 171,090 | \$ (10,196) | (6)% |
| Nutritional specialties | 29,247 | 24,222 | 5,025 | 21% | 55,551 | 46,592 | 8,959 | 19% |
| Vaccines | 16,951 | 11,713 | 5,238 | 45% | 31,729 | 23,956 | 7,773 | 32% |
| Animal Health | 123,673 | 121,504 | 2,169 | 2% | 248,174 | 241,638 | 6,536 | 3% |
| Mineral Nutrition | 56,699 | 58,853 | (2,154) | (4)% | 108,291 | 113,322 | (5,031) | (4)% |
| Performance Products | 11,226 | 11,416 | (190) | (2)% | 23,120 | 23,933 | (813) | (3)% |
| Total | \$ 191,598 | \$ 191,773 | \$ (175) | (0)% | \$ 379,585 | \$ 378,893 | \$ 692 | 0% |
| Adjusted EBITDA | | | | | | | | |
| Animal Health | \$ 34,609 | \$ 32,351 | \$ 2,258 | 7% | \$ 67,228 | \$ 63,827 | \$ 3,401 | 5% |
| Mineral Nutrition | 4,741 | 4,189 | 552 | 13% | 8,729 | 7,349 | 1,380 | 19% |
| Performance Products | 260 | (8) | 268 | * | 1,002 | 78 | 924 | 1185% |
| Corporate | (8,416) | (8,098) | (318) | * | (15,940) | (15,113) | (827) | * |
| Total | \$ 31,194 | \$ 28,434 | \$ 2,760 | 10% | \$ 61,019 | \$ 56,141 | \$ 4,878 | 9% |
| Adjusted EBITDA ratio to segment net sales | | | | | | | | |
| Animal Health | 28.0% | 26.6% | | | 27.1% | 26.4% | | |
| Mineral Nutrition | 8.4% | 7.1% | | | 8.1% | 6.5% | | |
| Performance Products | 2.3% | (0.1)% | | | 4.3% | 0.3% | | |

Edgar Filing: PHIBRO ANIMAL HEALTH CORP - Form 10-Q

| | | | | |
|--------------|--------|--------|--------|--------|
| Corporate(1) | (4.4)% | (4.2)% | (4.2)% | (4.0)% |
| Total(1) | 16.3% | 14.8% | 16.1% | 14.8% |

(1)
Reflects ratio to total net sales

*
Calculation not meaningful

The table below sets forth a reconciliation of net income, as reported under GAAP, to Adjusted EBITDA:

| For the Periods Ended December 31 | Three Months | | | Six Months | | | | |
|--|------------------------------------|-----------|-------------|------------|-----------|-----------|-------------|-------|
| | 2016 | 2015 | Change | 2016 | 2015 | Change | | |
| | (in thousands, except percentages) | | | | | | | |
| Net income | \$ 13,417 | \$ 30,178 | \$ (16,761) | (56)% | \$ 25,594 | \$ 48,931 | \$ (23,337) | (48)% |
| Interest expense, net | 3,872 | 3,967 | (95) | (2)% | 7,779 | 7,786 | (7) | (0)% |
| Provision (benefit) for income taxes | 5,887 | (14,081) | 19,968 | * | 11,282 | (9,342) | 20,624 | * |
| Depreciation and amortization | 6,444 | 5,393 | 1,051 | 19% | 12,762 | 10,822 | 1,940 | 18% |
| EBITDA | 29,620 | 25,457 | 4,163 | 16% | 57,417 | 58,197 | (780) | (1)% |
| Acquisition-related accrued compensation | 420 | 420 | — | 0% | 840 | 840 | — | 0% |
| Acquisition-related transaction costs | — | — | — | * | 1,274 | — | 1,274 | * |
| Pension settlement cost | 1,702 | — | 1,702 | * | 1,702 | — | 1,702 | * |
| Foreign currency (gains) losses, net | (548) | 2,557 | (3,105) | * | (214) | (2,896) | 2,682 | * |
| Adjusted EBITDA | \$ 31,194 | \$ 28,434 | \$ 2,760 | 10% | \$ 61,019 | \$ 56,141 | \$ 4,878 | 9% |

Amounts and percentages may reflect rounding adjustments.

*
Calculation not meaningful

TABLE OF CONTENTS

Comparison of the three months ended December 31, 2016 and 2015

Net sales

Net sales of \$191.6 million for the three months ended December 31, 2016, decreased \$0.2 million, or less than 1%, as compared to the three months ended December 31, 2015. Animal Health grew \$2.2 million, while Mineral Nutrition and Performance Products declined \$2.2 million and \$0.2 million, respectively.

Animal Health

Net sales of \$123.7 million for the three months ended December 31, 2016, grew \$2.2 million, or 2%. The growth was primarily due to volume increases in the nutritional specialty and vaccine product groups within the segment.

Nutritional specialty products grew \$5.0 million, or 21%, primarily due to volume growth of our products for the U.S. poultry and dairy industries. Vaccines grew \$5.2 million, or 45%, primarily due to volume growth of our products for the poultry and swine industries. The vaccine sales growth included products acquired from MVP Laboratories, Inc. in January 2016. Medicated feed additives (“MFAs”) and other declined \$8.1 million, or 9%, primarily due to international volume declines. International net sales declined due to economic conditions in Brazil and the timing of orders in certain other markets. Domestic net sales of MFAs and other declined modestly, as reduced volumes of medically important antibacterials were partially offset by growth in other products.

Mineral Nutrition

Net sales of \$56.7 million decreased \$2.2 million, or 4%, for the three months ended December 31, 2016. The reduced revenue was primarily due to lower average selling prices resulting from underlying raw material commodity price declines.

Performance Products

Net sales of \$11.2 million decreased \$0.2 million, or 2%, for the three months ended December 31, 2016, due to lower average selling prices of personal care ingredients and copper-based products and lower volumes of copper-based products. Higher volumes of personal care ingredients partially offset the declines.

Gross profit

Gross profit of \$63.5 million for the three months ended December 31, 2016, increased \$2.0 million, or 3%, as compared to the three months ended December 31, 2015. Gross profit increased to 33.1% of net sales for the three months ended December 31, 2016, as compared to 32.0% for the three months ended December 31, 2015. Animal Health gross profit increased \$1.2 million due to volume growth in nutritional specialty and vaccine products, as well as lower unit costs from improved operating efficiencies. Current year Animal Health gross profit was reduced by \$0.3 million of increased acquisition-related intangible amortization and \$1.0 million of increased depreciation expense due to recent capital expenditures. Mineral Nutrition gross profit increased \$0.5 million due to lower raw material costs, partially offset by lower average selling prices. Performance Products gross profit increased \$0.3 million due to higher volumes of personal care ingredients and lower product costs of copper-based products, partially offset by lower average selling prices of personal care ingredients and copper-based products.

Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of \$40.9 million for the three months ended December 31, 2016, increased \$2.0 million, or 5%, as compared to the three months ended December 31, 2015. During the three months ended December 31, 2016, we incurred \$1.7 million in expense relating to the partial settlement of our domestic noncontributory defined benefit pension plan. Excluding these costs, SG&A increased \$0.3 million, or 1%. Increased business development costs included in Corporate accounted for most of the increase.

Interest expense, net

Interest expense, net of \$3.9 million for the three months ended December 31, 2016, decreased \$0.1 million, or 2%, as compared to the three months ended December 31, 2015. Interest income increased

22

TABLE OF CONTENTS

\$0.4 million from interest on deposits in foreign jurisdictions. Interest expense increased \$0.4 million due to increased borrowings under our Revolver, compared to the three months ended December 31, 2015, and increased acquisition-related accrued interest.

Foreign currency (gains) losses, net

Foreign currency (gains) losses, net for the three months ended December 31, 2016, amounted to net gains of \$0.5 million, as compared to \$2.6 million in net losses for the three months ended December 31, 2015. Foreign currency gains in the three months ended December 31, 2016, were primarily due to the movement of the Turkish and Mexican currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.

Provision (benefit) for income taxes

The provision for income taxes was \$5.9 million for the three months ended December 31, 2016, as compared to an income tax benefit of \$14.1 million for the three months ended December 31, 2015. The effective income tax rates for these periods were 30.5% and (87.5)%, respectively. The large negative effective income tax rate for the three months ended December 31, 2015, was primarily due to the reversal of the valuation allowance we previously had recorded against domestic deferred tax assets. The reversal resulted in an income tax benefit of approximately \$18.8 million during the three months ended December 31, 2015. Excluding the effect of the reversal of the valuation allowance, the effective income tax rate for the three months ended December 31, 2015, was 29.2%.

Our future effective tax rate may be affected by discrete items, the fluctuation in tax rates in foreign jurisdictions and the amount of income earned in our foreign subsidiaries, some of which may have significant net operating loss carryforwards. As of December 31, 2016, we maintained a full valuation allowance against the deferred tax assets related to our foreign net operating loss carryforwards. We review the realizability of our deferred tax assets and evaluate our valuation allowances on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. We will continue to evaluate the necessity of these foreign valuation allowances in future periods, and to the extent that a positive earnings trend continues, a significant portion of these allowances may be released in future periods.

Net income

Net income of \$13.4 million for the three months ended December 31, 2016, decreased \$16.8 million, as compared to net income of \$30.2 million for the three months ended December 31, 2015. The decrease was a result of the factors described above, including an \$18.8 million income tax benefit in the prior year period, partially offset by a \$3.1 million favorable change in foreign currency (gains) losses, net.

Adjusted EBITDA

Adjusted EBITDA of \$31.2 million for the three months ended December 31, 2016, increased \$2.8 million, or 10%, as compared to the three months ended December 31, 2015. Animal Health Adjusted EBITDA increased \$2.3 million, or 7%, due to sales growth and increased gross profit, partially offset by increased SG&A. Mineral Nutrition increased \$0.6 million, or 13%, due to improved operating margins from lower raw material costs, partially offset by lower average selling prices. Performance Products increased \$0.3 million, due to higher volumes and lower product costs, partially offset by lower average selling prices. Corporate expenses increased \$0.3 million due to increased business development costs.

Comparison of the six months ended December 31, 2016 and 2015

Net sales

Net sales of \$379.6 million for the six months ended December 31, 2016, increased \$0.7 million, or less than 1%, as compared to the six months ended December 31, 2015. Animal Health grew \$6.5 million, while Mineral Nutrition and Performance Products declined \$5.0 million and \$0.8 million, respectively.

23

TABLE OF CONTENTS

Animal Health

Net sales of \$248.2 million for the six months ended December 31, 2016, grew \$6.5 million, or 3%. The growth was primarily due to volume increases in the nutritional specialty and vaccine product groups within the segment. Nutritional specialty products grew \$9.0 million, or 19%, primarily due to volume growth of our products for the U.S. poultry and dairy industries. Vaccines grew \$7.8 million, or 32%, primarily due to volume growth of our products for the poultry and swine industries. The vaccine sales growth included products acquired from MVP Laboratories, Inc. in January 2016. MFAs and other declined \$10.2 million, or 6%, primarily due to international volume declines. International net sales declined due to economic conditions in Brazil, partially offset by growth in other regions. Domestic net sales of MFAs and other declined as reduced volumes of medically important antibacterials were partially offset by growth in other products.

Mineral Nutrition

Net sales of \$108.3 million decreased \$5.0 million, or 4%, for the six months ended December 31, 2016. The reduced revenue was primarily due to lower average selling prices resulting from underlying raw material commodity price declines.

Performance Products

Net sales of \$23.1 million decreased \$0.8 million, or 3%, for the six months ended December 31, 2016, due to lower average selling prices of personal care ingredients and lower volumes of copper-based products and chemical catalyst products. Higher volumes of personal care ingredients partially offset the declines.

Gross profit

Gross profit of \$124.5 million for the six months ended December 31, 2016, increased \$3.8 million, or 3%, as compared to the six months ended December 31, 2015. Gross profit increased to 32.8% of net sales for the six months ended December 31, 2016, as compared to 31.8% for the six months ended December 31, 2015. Animal Health gross profit increased \$1.7 million due to volume growth in nutritional specialty and vaccine products, as well as lower unit costs from improved operating efficiencies. Current year Animal Health gross profit was reduced by \$0.6 million of increased acquisition-related intangible amortization and \$1.7 million of increased depreciation expense due to recent capital expenditures. Mineral Nutrition gross profit increased \$1.2 million due to lower raw material costs, partially offset by lower average selling prices. Performance Products gross profit increased \$0.8 million due to higher volumes of personal care ingredients and lower product costs of copper-based products, partially offset by lower average selling prices of personal care ingredients.

Selling, general and administrative expenses

SG&A of \$80.1 million for the six months ended December 31, 2016, increased \$3.9 million, or 5%, as compared to the six months ended December 31, 2015. During the six months ended December 31, 2016, we incurred \$1.3 million in acquisition-related transaction costs for professional fees and other items in the evaluation and negotiation of an unsuccessful acquisition. We also recorded \$1.7 million in costs relating to the partial settlement of the pension plan. Excluding these costs, SG&A increased \$0.9 million, or 1%.

Animal Health accounted for \$0.6 million of the increase, driven by increased sales force and development costs.

Mineral Nutrition SG&A decreased \$0.3 million due to one-time costs in the prior year. Corporate expenses accounted for \$0.6 million of the increase due to increased compensation and benefit costs and business development costs.

Interest expense, net

Interest expense, net of \$7.8 million for the six months ended December 31, 2016, decreased less than \$0.1 million, or less than 1%, as compared to the six months ended December 31, 2015. Interest expense increased \$1.1 million due to increased borrowings under our Revolver, compared to the six months ended December 31, 2015, and increased acquisition-related accrued interest. Interest income increased \$1.1 million from interest on deposits in foreign jurisdictions.

TABLE OF CONTENTS**Foreign currency (gains) losses, net**

Foreign currency (gains) losses, net for the six months ended December 31, 2016, amounted to net gains of \$0.2 million, as compared to \$2.9 million in net gains for the six months ended December 31, 2015. Foreign currency gains in the six months ended December 31, 2016, were primarily due to the movement of the Turkish and Mexican currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.

Provision (benefit) for income taxes

The provision for income taxes was \$11.3 million for the six months ended December 31, 2016, as compared to an income tax benefit of \$9.3 million for the six months ending December 31, 2015. The effective income tax rates for these periods were 30.6% and (23.6)%, respectively. The negative effective income tax rate for the six months ended December 31, 2015, was primarily due to a \$20.4 million income tax benefit from the reversal of the domestic valuation allowance we previously had recorded against domestic deferred tax assets and a benefit related to a discrete item. Excluding the effect of the reversal of the valuation allowance and the discrete item, the effective income tax rate for the six months ended December 31, 2015, was approximately 28.0%.

Our future effective tax rate may be affected by discrete items, the fluctuation in tax rates in foreign jurisdictions and the amount of income earned in our foreign subsidiaries, some of which may have significant net operating loss carryforwards. As of December 31, 2016, we maintained a full valuation allowance against the deferred tax assets related to our foreign net operating loss carryforwards. We review the realizability of our deferred tax assets and evaluate our valuation allowances on a quarterly basis, or whenever events or changes in circumstances indicate that a review is required. We will continue to evaluate the necessity of these foreign valuation allowances in future periods, and to the extent that a positive earnings trend continues, a significant portion of these allowances may be released in future periods.

Net income

Net income of \$25.6 million for the six months ended December 31, 2016, decreased \$23.3 million, as compared to net income of \$48.9 million for the six months ended December 31, 2015. The decrease was a result of the factors described above, including a \$20.4 million income tax benefit in the prior year period, plus an unfavorable change of \$2.7 million in foreign currency (gains) losses, net.

Adjusted EBITDA

Adjusted EBITDA of \$61.0 million for the six months ended December 31, 2016, increased \$4.9 million, or 9%, as compared to the six months ended December 31, 2015. Animal Health Adjusted EBITDA increased \$3.4 million, or 5%, due to sales growth and increased gross profit, partially offset by increased SG&A. Mineral Nutrition Adjusted EBITDA increased \$1.4 million, or 19%, due to improved operating margins from lower raw material costs, partially offset by lower average selling prices. Performance Products Adjusted EBITDA increased \$0.9 million, due to higher volumes and lower product costs, partially offset by lower average selling prices. Corporate expenses increased \$0.8 million due to increased compensation and benefit costs and business development costs.

Pension Plan and Retirement Savings Plan Changes

In July 2016, we amended our domestic noncontributory defined benefit pension plan to eliminate credit for future service and compensation increases, effective as of September 30, 2016. The amendment resulted in a curtailment of the pension plan. During the three months ended September 30, 2016, we recorded a pension curtailment gain of \$6.8 million in other comprehensive income and an offsetting reduction in the liability for pension benefits included in other liabilities. We also modified the 401(k) retirement savings plan effective October 1, 2016, to include, for all domestic employees, a non-elective Company contribution of 3% of compensation and an additional discretionary contribution of up to 4% of compensation, depending on the employee's age and years of service.

Separately, we offered a lump sum settlement option to certain pension plan participants. During the three months ended December 31, 2016, we recognized a partial settlement of the pension plan with respect to the lump sum settlement, which resulted in a charge to the consolidated statement of operations of \$1.7 million, which we recorded as a component of SG&A.

TABLE OF CONTENTS

Analysis of financial condition, liquidity and capital resources

Net increase (decrease) in cash and cash equivalents was:

| For the Periods Ended December 31 | Six Months | | |
|--|----------------|------------|-----------|
| | 2016 | 2015 | Change |
| | (in thousands) | | |
| Cash provided by/(used in): | | | |
| Operating activities | \$ 47,733 | \$ 5,604 | \$ 42,129 |
| Investing activities | (10,765) | (17,390) | 6,625 |
| Financing activities | (31,048) | 8,785 | (39,833) |
| Effect of exchange-rate changes on cash and cash equivalents | (305) | (843) | 538 |
| Net increase/(decrease) in cash and cash equivalents | \$ 5,615 | \$ (3,844) | \$ 9,459 |

Net cash provided (used) by operating activities was comprised of:

| For the Periods Ended December 31 | Six Months | | |
|---|----------------|-----------|-----------|
| | 2016 | 2015 | Change |
| | (in thousands) | | |
| EBITDA | \$ 57,417 | \$ 58,197 | \$ (780) |
| Acquisition-related accrued compensation | 840 | 840 | — |
| Acquisition-related transaction costs | 1,274 | — | 1,274 |
| Pension settlement cost | 1,702 | — | 1,702 |
| Foreign currency (gains) losses, net | (214) | (2,896) | 2,682 |
| Interest paid | (7,651) | (6,687) | (964) |
| Income taxes paid | (6,305) | (7,514) | 1,209 |
| Changes in operating assets and liabilities and other items | 670 | (36,336) | 37,006 |
| Net cash provided (used) by operating activities | \$ 47,733 | \$ 5,604 | \$ 42,129 |

Certain amounts and percentages may reflect rounding adjustments.

Operating activities

Net cash provided by operating activities was \$47.7 million for the six months ended December 31, 2016, primarily attributable to operating income of \$44.4 million and increases in changes in operating assets and liabilities of \$0.7 million. Decreased inventories provided \$7.0 million of cash due to timing of purchases and production. Accounts payable and accrued expenses used \$4.7 million of cash primarily due to timing of purchases, payments for annual incentive compensation and retirement plan funding. Accounts receivable used \$1.6 million of cash due to timing of sales and collections.

Investing activities

Net cash used in investing activities was \$10.8 million for the six months ended December 31, 2016. Capital expenditures were \$10.6 million as we continued to invest in our existing asset base and for capacity expansion and productivity improvements. Other investing activities used \$0.2 million of cash.

Financing activities

Net cash used by financing activities was \$31.0 million for the six months ended December 31, 2016. Net repayments on our Revolver used \$20.5 million. We paid \$7.9 million in dividends to holders of our Class A and Class B common stock. We paid \$2.8 million in scheduled debt and other requirements.

TABLE OF CONTENTS

Liquidity and capital resources

We believe our cash on hand and our financing arrangements, including the availability of borrowings under the Revolver, will be sufficient to support our future cash needs. Our operating plan projects adequate liquidity throughout the year. However, we can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the Revolver based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise. There can be no assurance that the challenging economic environment or an economic downturn would not impact our liquidity or our ability to obtain future financing. In addition, our debt covenants may restrict our ability to invest.

Certain relevant measures of our liquidity and capital resources were:

| As of | December 31, 2016 | June 30, 2016 | Change |
|--|-------------------------------|---------------|----------|
| | (in thousands, except ratios) | | |
| Cash and cash equivalents | \$ 39,220 | \$ 33,605 | \$ 5,615 |
| Working capital | 199,361 | 203,356 | (3,995) |
| Ratio of current assets to current liabilities | 2.99:1 | 2.92:1 | |

We define working capital as total current assets (excluding cash and cash equivalents) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition.

At December 31, 2016, our cash and cash equivalents included \$38.7 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries.

At December 31, 2016, we had \$48.5 million in outstanding borrowings under the Revolver. We had outstanding letters of credit and other commitments of \$14.5 million, leaving \$137.0 million available for borrowings and letters of credit.

We currently intend to pay quarterly dividends of \$0.10 per share, representing \$15.8 million annually on our Class A and Class B common stock, subject to approval from the Board of Directors. We declared and paid a cash dividend of \$0.10 per share on Class A common stock and Class B common stock during the three months ended December 31, 2016. On February 6, 2017, our Board of Directors declared a cash dividend of \$0.10 per share on each share of our Class A and Class B common stock outstanding on the record date of March 1, 2017, payable on March 22, 2017.

Contractual obligations

As of December 31, 2016, there were no material changes in payments due under contractual obligations from those disclosed in the Annual Report.

Off-balance sheet arrangements

We do not currently use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes.

In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations.

General description of non-GAAP financial measures

Adjusted EBITDA

Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors' understanding of our performance is enhanced by

TABLE OF CONTENTS

disclosing this performance measure. We report Adjusted EBITDA to portray the results of our operations prior to considering certain income statement elements. We have defined EBITDA as net income (loss) plus (i) interest expense, net, (ii) provision (benefit) for income taxes or less benefit for income taxes, and (iii) depreciation and amortization. We have defined Adjusted EBITDA as EBITDA plus (a) (income) loss from, and disposal of, discontinued operations, (b) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency gains and losses and loss on extinguishment of debt, and (c) certain items that we consider to be unusual, non-operational or non-recurring. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income (loss). The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income (loss).

The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis;
- our annual budgets are prepared on an Adjusted EBITDA basis; and
- other goal setting and performance measurements are prepared on an Adjusted EBITDA basis.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies.

Certain significant items

Adjusted EBITDA is calculated prior to considering certain items. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature.

New accounting standards

For discussion of new accounting standards, see “Notes to Consolidated Financial Statements— Summary of Significant Accounting Policies and New Accounting Standards.”

Critical Accounting Policies

Critical accounting policies are those that require application of management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all of these significant accounting policies require management to make difficult, subjective or complex judgments or estimates. However, management is required to make certain estimates and assumptions during the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Significant estimates include depreciation and amortization periods of long-lived and intangible assets, recoverability of long-lived and intangible assets and goodwill,

realizability of deferred income tax

28

TABLE OF CONTENTS

and value-added tax assets, legal and environmental matters and actuarial assumptions related to our pension plans. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period they are determined to be necessary. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in the Annual Report. Except as described below, as of December 31, 2016, there have been no material changes to any of the critical accounting policies contained therein.

We applied Accounting Standards Update (“ASU”) 2015-03, Interest—Imputation of Interest (Subtopic 835-30), effective July 1, 2016. All prior periods have been adjusted to reflect the retrospective application of this guidance, which requires that certain debt issuance costs be classified as a reduction of the related liability. Debt issuance costs were previously classified as an asset.

Forward-Looking Statements

This report contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected earnings, revenues, costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, or the expected outcome or impact of pending or threatened litigation are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Examples of such risks and uncertainties include:

- perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products;
- restrictions on the use of antibacterials in food-producing animals may become more prevalent;
- a material portion of our sales and gross profits are generated by antibacterials and other related products;
- competition in each of our markets from a number of large and small companies, some of which have greater financial, research and development, production and other resources than we have;
- the impact of current and future laws and regulatory changes;
- outbreaks of animal diseases could significantly reduce demand for our products;
- our ability to successfully implement several of our strategic initiatives;
- the effect of weather conditions and the availability of natural resources;

- the continuing trend toward consolidation of certain customer groups as well as the emergence of large buying groups;
- our ability to control costs and expenses;
- any unforeseen material loss or casualty;
- exposure relating to rising costs and reduced customer income;

TABLE OF CONTENTS

- competition deriving from advances in veterinary medical practices and animal health technologies;
- unanticipated safety or efficacy concerns;
- our dependence on suppliers having current regulatory approvals;
- our raw materials are subject to price fluctuations and their availability can be limited;
- natural and man-made disasters, including but not limited to fire, snow and ice storms, flood, hail, hurricanes and earthquakes;
- terrorist attacks, particularly attacks on or within markets in which we operate;
- our reliance on the continued operation of our manufacturing facilities and application of our intellectual property;
- adverse U.S. and international economic market conditions, including currency fluctuations;
- the risks of product liability claims, legal proceedings and general litigation expenses;
- our dependence on our Israeli and Brazilian operations;
- our substantial level of indebtedness and related debt-service obligations;
- restrictions imposed by covenants in our debt agreements;
- the risk of work stoppages; and
- other factors as described in “Risk Factors” in Item 1A. of the Annual Report.

While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Annual Report. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

In the normal course of operations, we are exposed to market risks arising from adverse changes in interest rates, foreign currency exchange rates and commodity prices. As a result, future earnings, cash flows and fair values of assets and liabilities are subject to uncertainty. We use, from time to time, foreign currency contracts as a means of hedging exposure to foreign currency risks. We also utilize, on a limited basis, certain commodity derivatives, primarily on copper used in manufacturing processes, to hedge the cost of anticipated purchase or supply requirements. We do not utilize derivative instruments for trading or speculative purposes. We do not hedge our exposure to market risks in a manner that completely eliminates the effects of changing market conditions on earnings, cash flows and fair values. We monitor the financial stability and credit standing of our major counterparties.

30

TABLE OF CONTENTS

For financial market risks related to changes in interest rates, foreign currency exchange rates and commodity prices, reference is made to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Qualitative and Quantitative Disclosures about Market Risk” section in the Annual Report and to the notes to the consolidated financial statements included therein. There were no material changes in the Company’s financial market risks from the risks disclosed in the Annual Report.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”). Based upon that evaluation as of December 31, 2016, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were not effective because of material weaknesses in our internal control over financial reporting, as described in Management’s Report on Internal Control Over Financial Reporting in “Item 9A. Controls and Procedures” in the Annual Report on Form 10-K for the year ended June 30, 2016.

Management’s Remediation Plan

Management has begun implementing changes to our internal control over financial reporting to remediate the material weaknesses that existed as of June 30, 2016. Our remediation plan includes (i) designing and implementing additional formal accounting policies and procedures and (ii) restricting access to key financial systems and records to appropriate users to ensure that appropriate segregation of duties is maintained. Recent actions taken to address material weaknesses include the design and implementation of certain formal accounting policies and procedures, as well as restricting certain access to users of key financial systems and records. We will continue to build on the progress we have made in our remediation plan. We cannot determine when our remediation plan will be fully completed, and we cannot provide any assurance that these remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended December 31, 2016, that materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

31

TABLE OF CONTENTS

PART II—OTHER INFORMATION

Item 1.

Legal Proceedings

Information required by this Item is incorporated herein by reference to “Notes to the Consolidated Financial Statements—Commitments and Contingencies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.

Item 1A.

Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Risk Factors” section in the Annual Report, which could materially affect our business, financial condition or future results.

There were no material changes in the Company’s risk factors from the risks disclosed in the Annual Report.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

None.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit 10.36* Amendment No. 2 to Credit Agreement, dated December 23, 2016, among Phibro Animal Health Corporation, Bank of America, N.A., and Coöperatieve Rabobank U.A., New York Branch (f/k/a Coöperatieve Centrale Raiffeisen-Boerenleenbank, B.A., “Rabobank Nederland,” New York Branch)

Exhibit 31.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302

Exhibit 31.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302

Exhibit 32.1 Chief Executive Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906

Exhibit 32.2 Chief Financial Officer—Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906

Exhibit 101.INS** XBRL Instance Document

Exhibit 101.SCH** XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit 101.DEF** XBRL Taxonomy Extension Definition Linkbase Document

Exhibit 101.LAB** XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE** XBRL Taxonomy Extension Presentation Linkbase Document

32

TABLE OF CONTENTS

*

Incorporated by reference to Current Report on Form 8-K dated December 23, 2016.

**

Furnished with this Quarterly Report. Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933 and are deemed not filed for purposes of section 18 of the Exchange Act.

33

TABLE OF CONTENTS

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Phibro Animal Health Corporation

/s/ Jack C. Bendheim

February 6, 2017 By: Jack C. Bendheim
President and Chief Executive Officer
/s/ Richard G. Johnson

February 6, 2017 By: Richard G. Johnson
Chief Financial Officer